2025 Canadian Guide: Top 5 Prescription NSAID Options for Dogs — Topical Gels & Sprays plus Trusted Oral Alternatives (Veterinarian-Reviewed, Compare Surpass, Metacam, Rimadyl and More)

Surpass is positioned as the topical NSAID option for canine musculoskeletal pain, offering localized delivery that can reduce systemic exposure compared with oral agents on this list. For the specific use case of prescription topical gels and sprays, it stands out technically by providing targeted anti-inflammatory action at the application site, which can translate to lower monitoring and GI-risk-related costs versus systemic NSAIDs like Rimadyl or Metacam. While systemic drugs may provide broader pain control for generalized disease, Surpass’s financial advantage is often lower ancillary testing and fewer dispensing restrictions when used in focal conditions.

Metacam (meloxicam) is a widely used oral NSAID noted for its once-daily dosing and broad availability, which often makes it a market leader on cost-per-dose and formulary inclusion compared with some branded chewables. In the context of topical alternatives, Metacam provides systemic therapy that treats diffuse or severe inflammatory conditions beyond the reach of localized topicals like Surpass, but it typically requires more routine safety monitoring, an important financial consideration for long-term therapy. Its global manufacturer footprint and generic options in many regions also tend to keep acquisition costs competitive versus some COX-2 selective chewables.

Rimadyl (carprofen) is a long-established oral NSAID with extensive clinical use and brand recognition, often chosen for its predictable analgesic profile and palatable chewable format that helps with owner compliance compared to topical-only approaches. Against topical Surpass it provides systemic control for multi-joint disease, and versus other chewable competitors it frequently competes on price and generic availability, giving it a favorable financial position for clinics managing chronic osteoarthritis. While systemic by nature, Rimadyl’s large safety database can reduce perceived risk for prescribers when compared to newer agents.

Previcox (firocoxib) is a COX-2–selective oral NSAID that is often positioned for once-daily convenience and a safety profile that many clinicians prefer for chronic management, making it a market leader among COX-2 selective chewables. For the topical-use focused list, Previcox represents the systemic, longer-acting alternative that can reduce dosing frequency and improve adherence compared with multiple daily topical applications, though it usually carries higher per-tablet pricing than some generic options. Its technical advantage is selectivity for inflammatory pathways, which can be a differentiator when comparing adverse-event monitoring and downstream healthcare costs to nonselective NSAIDs.